Stockreport

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Patent protection extended through 2043Alzheimer's proof-of-concept study completedClinical and Biomarker Outcomes Expected in Q1 2026CAMBRIDGE, Mass., Jan. 21, 2026 /PR [Read more]